Literature DB >> 2839637

Duration of occupancy of opiate receptors by naltrexone.

M C Lee1, H N Wagner, S Tanada, J J Frost, A N Bice, R F Dannals.   

Abstract

To determine the duration of blockade of mu-opiate receptors by naltrexone, we measured the binding of [11C]carfentanil in the brain of five normal volunteers with a positron radiation detection system before and 1, 48, 72, 120, and 168 hr after naltrexone administration. The half-time of blockade by naltrexone in the brain ranged from 72 to 108 hr which is greater than the fast plasma clearance components (4-12 hr) of naltrexone or its metabolite, beta-naltrexol, but corresponds well to the half-time of the terminal phase of plasma naltrexone clearance (96 hr). These results are consistent with the duration of the pharmacologic effects of naltrexone in response to heroin administration and indicate that 50 mg/day of oral naltrexone results in plasma levels in excess of that needed to saturate opiate receptors. This is the first example of the use of a simple dual-detector system with positron-emitting radioactive drugs to provide information regarding the duration of action of the drug on its specific receptor site. The plasma clearance half-time of a drug may not give an accurate reflection of the duration of action of the drug on a specific neuroreceptor site. Direct measurement of drug effects on recognition sites greatly extend current studies of pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839637

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  55 in total

1.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 2.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

4.  Reduction of conditioned pain modulation in humans by naltrexone: an exploratory study of the effects of pain catastrophizing.

Authors:  Christopher D King; Burel Goodin; Lindsay L Kindler; Robert M Caudle; Robert R Edwards; Nikolaus Gravenstein; Joseph L Riley; Roger B Fillingim
Journal:  J Behav Med       Date:  2012-04-26

Review 5.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 6.  Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man.

Authors:  B Sadzot; G Franck
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 7.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

8.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

9.  Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.

Authors:  Jarred W Younger; Alex J Zautra; Eric T Cummins
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.